{"id":"lpcn-1144-formulation-b","safety":{"commonSideEffects":[{"rate":null,"effect":"Erectile dysfunction"},{"rate":null,"effect":"Acne"},{"rate":null,"effect":"Hypertension"}]},"_chembl":{"chemblId":"CHEMBL5998293","moleculeType":null,"molecularWeight":"520.61"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by increasing testosterone levels in the body, which can help alleviate symptoms of hypogonadism such as low libido and fatigue. LPCN 1144 Formulation B is designed to provide a more consistent and predictable release of testosterone compared to traditional formulations.","oneSentence":"LPCN 1144 Formulation B is a testosterone replacement therapy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:38:41.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of hypogonadism in men"}]},"trialDetails":[{"nctId":"NCT04134091","phase":"PHASE2","title":"The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis","status":"COMPLETED","sponsor":"Lipocine Inc.","startDate":"2019-08-27","conditions":"Nonalcoholic Steatohepatitis (NASH)","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["testosterone undecanoate with d-alpha tocopherol"],"phase":"phase_2","status":"active","brandName":"LPCN 1144 Formulation B","genericName":"LPCN 1144 Formulation B","companyName":"Lipocine Inc.","companyId":"lipocine-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LPCN 1144 Formulation B is being studied in a Phase 2 clinical trial for the treatment of Nonalcoholic Steatohepatitis (NASH). The study is a randomized double-blind, placebo-controlled trial that also includes LPCN 1144 Formulation A as an intervention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}